CLDX
Celldex Therapeutics Inc
31.70$
-1.6%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| -9.1% | -25.0% | -18.2% | -48.0% | -90.3% | 1.1% | 0.6% | – | – | 280.9% | 357.7% | 480.2% | 522.0% | 55.3% | 25.8% | 98.4% | 96.2% | 56.8% | 94.8% | 73.2% | 1,503.5% | 754.7% | 696.7% | 1,194.3% | 573.4% | 1,146.2% | 3,489.9% | 1,714.5% | 2,329.8% | – | |
| 109.1% | 125.0% | 118.2% | 148.0% | 190.3% | 98.9% | 99.4% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 44.7% | 74.2% | 1.6% | 3.8% | 43.2% | 5.2% | 26.8% | -1,403.5% | -654.7% | -596.7% | -1,094.3% | -473.4% | -1,046.2% | -3,389.9% | -1,614.5% | -2,229.8% | 100.0% | |
| 545.5% | 441.7% | 259.1% | 530.6% | 1,411.7% | 645.0% | 219.4% | 216.3% | 202.3% | 455.4% | 366.4% | 362.5% | 353.4% | 172.4% | 59.1% | 350.1% | 423.1% | 1,639.5% | 2,910.8% | 1,827.9% | 1,513.8% | 754.7% | 696.7% | 1,194.3% | 546.4% | 1,221.5% | 3,489.9% | 1,714.5% | 2,329.8% | 16,340.0% | |
| 590.9% | 291.7% | 172.7% | 288.5% | 630.0% | 146.9% | 83.4% | 115.5% | 81.2% | 223,257.4% | 167,039.0% | 166,608.0% | 197,805.4% | 112.8% | 22.3% | 99.8% | 89.4% | 360.1% | 575.1% | 617.5% | 530.2% | 196.2% | 202.0% | 431.7% | 194.9% | 440.5% | 1,153.8% | 449.1% | 549.1% | 2,920.0% | |
| 1,181.8% | 766.7% | 477.3% | 953.2% | 2,213.5% | 833.0% | 314.6% | 353.3% | 298.0% | 710.8% | 553.6% | 547.9% | 556.0% | 287.4% | 88.0% | 470.5% | 522.3% | 2,024.3% | 3,419.3% | 635.9% | 555.2% | 299.0% | 1,043.5% | 445.9% | 380.7% | 485.6% | 1,499.1% | 630.7% | 549.1% | 19,260.0% | |
| -1,072.7% | -641.7% | -361.3% | -805.1% | -2,023.2% | -734.1% | -215.2% | -253.3% | -198.0% | -610.8% | -453.6% | -447.9% | -456.0% | -216.4% | -13.8% | -468.4% | -518.5% | -1,981.1% | -3,414.1% | -2,363.9% | -1,958.7% | -953.7% | -1,640.1% | -1,540.2% | -854.1% | -1,531.8% | -4,889.0% | -2,245.3% | -2,778.9% | -19,160.0% | |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 85.7% | 43.0% | 2.1% | 3.0% | 2.9% | 19.4% | 14.1% | 22.5% | 0.0% | 0.0% | 0.0% | 125.3% | 1,584.1% | 0.0% | 253.7% | 2.4% | 123.4% | – | – | – | |
| -981.8% | -1,100.0% | -359.1% | -762.3% | -2,879.3% | -680.0% | -206.3% | -248.1% | -192.5% | -586.0% | -410.7% | -426.4% | -637.1% | -244.1% | -5.4% | -483.5% | -527.8% | -1,983.7% | -3,292.8% | -2,321.1% | -1,894.0% | -920.6% | -1,593.1% | -1,424.0% | -821.6% | -1,520.9% | -4,765.6% | -2,054.8% | -2,248.8% | -17,253.3% | |
| -181.8% | 908.3% | 3,986.4% | -85.6% | 1,712.3% | -108.1% | -18.0% | 15.0% | -11.0% | -49.8% | 2.4% | -2.4% | 362.2% | -3.5% | -11.3% | -4.8% | -4.7% | -19.9% | -121.3% | -42.8% | -129.3% | -190.6% | -8.0% | -14.2% | -15.7% | -4.9% | 443.7% | 41.3% | -2,248.8% | – | |
| -981.8% | -1,091.7% | -2,354.5% | -762.3% | -2,879.3% | -680.0% | -206.3% | -273.5% | -192.5% | -586.0% | -413.2% | -424.0% | -637.1% | -240.6% | -5.4% | -483.5% | -527.8% | -1,983.7% | -3,292.8% | -2,321.1% | -1,894.0% | -730.1% | -1,585.1% | -1,424.0% | -805.9% | -1,516.0% | -4,765.6% | -2,054.8% | -2,248.8% | -17,253.3% | |
| -1,027.3% | -609.0% | -315.9% | -671.1% | -1,851.4% | -666.6% | -191.1% | -220.3% | -172.3% | -534.4% | -368.2% | -373.7% | -603.1% | -217.9% | 10.0% | -419.2% | -485.7% | -1,889.5% | -3,198.0% | -2,290.7% | -1,833.7% | -816.3% | -761.2% | -1,390.1% | -615.3% | -1,420.8% | -4,420.9% | -2,020.0% | -2,203.5% | -17,028.0% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.